Compared with annual screening for urinary albumin, personalized screening can reduce time spent with undetected albuminuria, testing frequency
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.
Finerenone, a mineralocorticoid receptor antagonist, may exert anti-inflammatory and anti-fibrotic effects, according to investigators.
The consensus report highlights shared guideline recommendations from the ADA 2022 Standards of Medical Care in Diabetes and KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.
Blockading the mineralocorticoid receptor may be another strategy to treat CKD in patients with type 2 diabetes.
A multicenter randomized controlled trial was conducted to assess the impact of a web-based, diabetes evaluation portal and team-based care on outcomes in patients with diabetic kidney disease.
Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk
A study conducted in Taiwan is the first to show that hyperuricemia is as risky as diabetes in contributing to ESKD and death risk in patients with stage 3 to 5 CKD.
Study findings suggest the nephroprotective effects of both drug classes are complementary.